131 e-Letters

published between 2005 and 2008

  • Should patients with medium risk of disease progression really be avoided in clinical trials?
    Jane S Angwin

    Dear Editor,

    Patient selection can affect required sample sizes and outcomes in randomised clinical trials and the optimal selection may depend on how the tested drug differentially affects patients. Bruynesteyn K et al. [1,2] have investigated these effects in rheumatoid arthritis based on an outcome measure of radiological damage progression.

    An absolute reduction (AR) drug which reduces the expe...

    Show More